ストックスクリーナーアプリを入手
1.80
1.69%
0.03
前日終値:
$1.77
開ける：
$1.8
24時間の取引高:
312.54K
Relative Volume:
1.54
時価総額：
$54.56M
収益：
-
当期純損益:
$-25.94M
株価収益率:
-1.3043
EPS:
-1.38
ネットキャッシュフロー:
$-15.79M
1週間 パフォーマンス:
-11.76%
1か月 パフォーマンス:
+16.88%
6か月 パフォーマンス:
-20.35%
1年 パフォーマンス:
-42.31%
1日の値動き範囲:
$1.75
$1.86
1週間の範囲:
$1.69
$2.08
52週間の値動き範囲:
$1.40
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
名前
MAIA Biotechnology Inc
セクター
電話
312 416 8592
住所
444 West Lake Street, Suite 1700, Chicago
MAIA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.80 | 60.36M | 0 | -25.94M | -15.79M | -1.38 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
MAIA Biotechnology Inc (MAIA) 最新ニュース
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks
MAIA Biotechnology launches $1.08M private placement - MSN
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com
MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com
MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com
MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World
MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN
MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India
MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener
MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com
Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? - Insider Monkey
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025 - TipRanks
Q1 EPS Forecast for MAIA Biotechnology Lifted by Analyst - Defense World
MAIA Biotechnology revises offering to $11.2 million By Investing.com - Investing.com Australia
Diamond Equity Comments on MAIA Biotechnology Q1 Earnings - Defense World
MAIA Biotechnology revises offering to $11.2 million - Investing.com
Maia Biotechnology IncDecreases Maximum Aggregate Offering Price To $11.2 MillionSEC Filing - Marketscreener.com
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - BioSpace
Breakthrough Lung Cancer Drug Shows Exceptional Phase 2 Results: Key Biomarker Discovery - Stock Titan
Maia Bio touts two advances for its lead cancer drug in development - Crain's Chicago Business
MAIA Biotechnology reports breakthrough in cancer treatment research By Investing.com - Investing.com South Africa
MAIA Biotechnology advances with new drug name approval By Investing.com - Investing.com Australia
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - BioSpace
MAIA Biotechnology reports breakthrough in cancer treatment research - Investing.com
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - BioSpace
Maia Biotechnology Receives Usan Council Approval For "Ateganosine" As Nonproprietary Name For Anticancer Agent Thio - Marketscreener.com
MAIA Biotechnology advances with new drug name approval - Investing.com
MAIA Biotechnology receives USAN Council approval for ‘Ateganosine’ name - TipRanks
MAIA Biotechnology, Inc. Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO - Marketscreener.com
MAIA Biotechnology Inc (MAIA) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):